WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H206484
CAS#: 1265965-22-7
Description: S-49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3. A phase I study with S-49076 is currently underway in patients with advanced solid tumors.
Hodoodo Cat#: H206484
Name: S-49076
CAS#: 1265965-22-7
Chemical Formula: C22H22N4O4S
Exact Mass: 438.14
Molecular Weight: 438.500
Elemental Analysis: C, 60.26; H, 5.06; N, 12.78; O, 14.59; S, 7.31
Synonym: S-49076; S49076; S 49076.
IUPAC/Chemical Name: (Z)-3-((3-((4-(morpholinomethyl)-1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)methyl)thiazolidine-2,4-dione
InChi Key: AREYWCZYVPSHGS-NVMNQCDNSA-N
InChi Code: InChI=1S/C22H22N4O4S/c27-20-13-31-22(29)26(20)12-14-1-2-19-17(8-14)18(21(28)24-19)9-16-7-15(10-23-16)11-25-3-5-30-6-4-25/h1-2,7-10,23H,3-6,11-13H2,(H,24,28)/b18-9-
SMILES Code: O=C(N1CC2=CC3=C(NC(/C3=C\C4=CC(CN5CCOCC5)=CN4)=O)C=C2)SCC1=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# 1265965-22-7(S-49076 Free Base) 1265966-31-1(722572
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 438.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Léonce S, Ferry G, Da
Violante G, Bouzom F, Cattan V, Jacquet-Bescond A, Comoglio PM, Lockhart BP,
Boutin JA, Cordi A, Ortuno JC, Pierré A, Hickman JA, Cruzalegui FH, Depil S.
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical
activity alone and in association with bevacizumab. Mol Cancer Ther. 2013
Sep;12(9):1749-62. doi: 10.1158/1535-7163.MCT-13-0075. Epub 2013 Jun 26. PubMed
PMID: 23804704.